MDGL

Madrigal Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

296.380

-2.02(-0.677%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

305.000

Open

298.100

VWAP

Vol

160.16K

Mkt Cap

6.63B

Low

295.150

Amount

EV/EBITDA(TTM)

Total Shares

21.31M

5.90B

EV/OCF(TTM)

P/S(TTM)

20.49

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

180.76M

+190.74%

-3.314

+22.27%

159.40M

+988.97%

-3.452

-29.83%

-3.631

-48.85%

Estimates Revision

The market is revising Upward the revenue expectations for Madrigal Pharmaceuticals, Inc. (MDGL) for FY2025, with the revenue forecasts being adjusted by 14.76% over the past three months. During the same period, the stock price has changed by -10.54%.

Revenue Estimates for FY2025

Revise Upward

+14.76%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+2.01%

In Past 3 Month

Stock Price

Go Down

-10.54%

In Past 3 Month

14 Analyst Rating

44.30% Upside

Wall Street analysts forecast MDGL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDGL is 427.67 USD with a low forecast of 248.00 USD and a high forecast of 540.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Buy

1 Hold

1 Sell

Strong Buy

44.30% Upside

Current: 296.380

Low

248.00

Averages

427.67

High

540.00

44.30% Upside

Current: 296.380

Low

248.00

Averages

427.67

High

540.00

Piper Sandler

Overweight

maintain

$400

2025-07-16

Reason

Piper Sandler

Price Target

$400

2025-07-16

maintain

Overweight

Reason

Piper Sandler keeps an Overweight rating on Madrigal Pharmaceuticals with a $400 price target after the company received a notice of allowance from the Patent and Trademark Office covering the use of Rezdiffra. The news "presents a significant win and stock-moving event," the analyst tells investors in a research note. The firm believes the patent bolsters Rezdiffra's blockbuster potential. The drug is on track to cross $1Bannual sales in 2026, and represents a $5B opportunity, especially with patent coverage out to 2044, contends Piper. Madrigal in premarket trading is up 6% to $330.00.

Citigroup

David Lebovitz

Strong Buy

Maintains

$378 → $469

2025-02-27

Reason

Citigroup

David Lebovitz

Price Target

$378 → $469

2025-02-27

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Ed Arce

Strong Buy

Maintains

$400 → $405

2025-02-27

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$400 → $405

2025-02-27

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Ed Arce

Strong Buy

Maintains

$390 → $400

2025-01-14

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$390 → $400

2025-01-14

Maintains

Strong Buy

Reason

JMP Securities

Jonathan Wolleben

Buy

Reiterates

$427

2025-01-10

Reason

JMP Securities

Jonathan Wolleben

Price Target

$427

2025-01-10

Reiterates

Buy

Reason

Cantor Fitzgerald

Prakhar Agrawal

Hold

Reiterates

n/a

2024-11-20

Reason

Cantor Fitzgerald

Prakhar Agrawal

Price Target

n/a

2024-11-20

Reiterates

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Madrigal Pharmaceuticals Inc (MDGL.O) is -27.85, compared to its 5-year average forward P/E of -10.11. For a more detailed relative valuation and DCF analysis to assess Madrigal Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-10.11

Current PE

-27.85

Overvalued PE

-3.77

Undervalued PE

-16.45

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-7.23

Current EV/EBITDA

-18.69

Overvalued EV/EBITDA

-3.15

Undervalued EV/EBITDA

-11.30

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

47.15

Current PS

8.66

Overvalued PS

146.83

Undervalued PS

-52.52